Thank you nicely 😜. I really appreciate your support. No major changes from the previous guidance as such but they make references to the technology appraisals on SGLT2 inhibitors for heart failure which have changed relatively recently with dapaglifozin and empaglifozin being recommended for both HFrEF and HFpEF
Good summary 👍
Thank you very much for your support. It helps a lot 🙏
Nicely summarised (no pun intended...) were there any changes to previous guidance?
Thank you nicely 😜. I really appreciate your support. No major changes from the previous guidance as such but they make references to the technology appraisals on SGLT2 inhibitors for heart failure which have changed relatively recently with dapaglifozin and empaglifozin being recommended for both HFrEF and HFpEF